Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.
Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.
QuidelOrtho (Nasdaq: QDEL) said members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference on Tuesday, March 3, 2026 at 1:40 p.m. ET / 10:40 a.m. PT.
According to the company, a live webcast and replay will be available in the Events & Presentations section of its Investor Relations website.
QuidelOrtho (Nasdaq: QDEL) reported fourth-quarter and full-year 2025 results: FY25 revenue $2.73B, adjusted EBITDA $597M with a 22% margin (up 240 bps), and adjusted diluted EPS $2.12. GAAP results included a $701M goodwill impairment, producing a FY25 GAAP net loss of $1.13B and GAAP diluted loss per share of $16.69. The company provided FY26 guidance of $2.7–$2.9B revenue, adjusted EBITDA $630–$670M, adjusted diluted EPS $2.00–$2.42, and free cash flow of $120–$160M. CFO Joseph Busky will retire effective June 30, 2026.
QuidelOrtho (Nasdaq: QDEL) received the Excellence Services Label in EMEA for Customer and Technical Services evaluated to ISO 23592 and is the first medical device company to earn that distinction. QuidelOrtho also won a Gold Stevie for Customer Service Success and a Bronze Stevie for AI & Tech Focused Digital Transformation Team.
The ISO 23592 scope covers Customer Service, Technical Solutions, Technical Training and Field Service; the label affirms maturity and consistent customer focus, while Stevie recognition highlights customer‑experience and digital transformation efforts.
QuidelOrtho (Nasdaq: QDEL) released episode 55 of its Science Bytes podcast on Jan 22, 2026, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. Mullens discusses pressures on the blood supply from routine trauma and climate-driven emergencies, rising demand for O-type units due to low-titer whole blood programs, the role of automation in immunohematology, and the importance of year-round donor engagement. The episode highlights the link between donors, diagnostics, and patient care and is available on major streaming platforms and the company's website.
QuidelOrtho (Nasdaq: QDEL) will report fourth quarter and full-year 2025 financial results for the period ended December 28, 2025, after market close on Wednesday, February 11, 2026. A conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET the same day, with presentation materials and a replay available in the Events & Presentations section of the company's Investor Relations website.
Investors can join the live webcast via the IR site or by phone at 833-470-1428 (U.S.) or +1 929-526-1599 (international) using Conference ID 690468.
QuidelOrtho (Nasdaq: QDEL) released Episode 54 of its Science Bytes podcast on Dec. 18, 2025, featuring Jonathan Siegrist, PhD, EVP of Research & Development and CTO.
Key topics include high-sensitivity troponin for faster cardiac diagnosis, non-invasive gastrointestinal assays, rapid combo respiratory tests, advances in molecular platforms, informatics and AI, and R&D strategies to scale diagnostic innovation globally. The episode discusses how these technologies streamline clinical workflows and support timely patient care decisions.
The podcast is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) announced that management will participate in two investor conferences in early December 2025: the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025 with a fireside chat at 10:00 a.m. ET / 7:00 a.m. PT, and the Citi Global Healthcare Conference on December 3, 2025 with a fireside chat at 1:00 p.m. ET / 10:00 a.m. PT.
Investors can access the live webcasts and replays in the Events & Presentations section of QuidelOrtho's Investor Relations site at https://ir.quidelortho.com/.
QuidelOrtho (Nasdaq: QDEL) released Episode 53 of its Science Bytes podcast on Nov 20, 2025, featuring Dr. Qian Ding discussing early detection of diabetes.
Key points: early testing can change patient trajectories; emerging biomarkers (C-peptide, pro‑insulin, adiponectin) add metabolic insight beyond glucose; automation-ready lab platforms speed reliable results; early detection supports value-based care and may reduce costly interventions; tailored testing promotes equity across populations. The episode is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) launched the QUICKVUE Influenza + SARS Test, a CLIA‑waived, 510(k)‑cleared rapid immunoassay for professional use that detects and differentiates influenza A, influenza B and SARS‑CoV‑2 antigens from a single nasal swab.
The visually read combo test delivers results in as fast as 10 minutes, is designed for physician office labs, urgent care, emergency departments, pharmacies and decentralized hospital labs, and complements QuidelOrtho's instrumented SOFIA 2 Flu + SARS product as a cost‑effective point‑of‑care option. The test is available in the United States through existing distribution channels and is not intended for in‑home use.
QuidelOrtho (Nasdaq: QDEL) reported Q3 2025 total revenue of $700 million and an adjusted diluted EPS of $0.80. GAAP results included a $701 million non-cash goodwill impairment/b), producing a and GAAP diluted loss per share of $10.78. Adjusted EBITDA was $177 million with a 25% margin. The company completed a debt refinancing to improve financial flexibility and narrowed full-year 2025 guidance to $2.68–$2.74 billion revenue, $585–$605 million adjusted EBITDA, and $2.00–$2.15 adjusted diluted EPS. Q3 results reflected a 63% decline in COVID-19 revenue and continued wind-down of the U.S. Donor Screening portfolio.